Subscribe to PCMR and stay up-to-date with the only journal committed to publishing basic research in melanoma and pigment cell biology As a member of the IFPCS or the SMR you automatically get online access to PCMR. Sign up as a member today at www.ifpcs.org or at www.societymelanomaresarch.org however, almost all invariably relapse with drug-resistant disease. Here, we report that microRNA-125a (miR125a) expression is upregulated in human melanoma cells and patient tissues upon acquisition of BRAFi resistance. We show that miR-125a induction confers resistance to BRAF V600E melanoma cells to BRAFi by directly suppressing pro-apoptotic components of the intrinsic apoptosis pathway, including BAK1 and MLK3.
Introduction
Melanoma is the leading cause of death from skin cancer, with incidence that continues to rise (Ferlay et al., 2015) . Somatic, activating mutations in BRAF, predominantly V600E, occur in~40-50% of cutaneous malignant melanomas (Akbani et al., 2015; Krauthammer et al., 2015) , and BRAF inhibitors (BRAFi) have become important therapeutic agents in the treatment of metastatic BRAF V600E melanoma (Bollag et al., 2010; Chapman et al., 2011; Flaherty et al., 2010; Sosman et al., 2012) . Initial responses to BRAFi are exceptional with metastatic tumors that routinely vanish in clinical imaging of treated patients; however, tumor cells are not completely eradicated and resistance of melanoma cells to these inhibitors occurs in nearly all patients, resulting in progression with treatment refractory disease. Numerous molecular mechanisms involved in the acquisition of BRAFi resistance have been reported. Most resistance mechanisms involve reactivation of the MAPK pathway, commonly through NRAS mutation (Nazarian et al., 2010) , BRAF splicing changes (Poulikakos et al., 2011) or amplification (Shi et al., 2012) , but also through less frequent alterations, such as MEK1/2 mutation (Emery et al., 2009) , COT hyperactivation (Johannessen et al., 2010) , or RTK/EGF receptor upregulation (Girotti et al., 2013) . Alternatively, the PI3K/AKT pathway [i.e., PTEN loss (Paraiso et al., 2011) , AKT hyperactivation (Shao and Aplin, 2010) , NF1 loss (Whittaker et al., 2013) , PIP3 loss (Ye et al., 2013) , IGF1R upregulation (Villanueva et al., 2010) ], or additional mechanisms (Haq et al., 2013b; Hilmi et al., 2008; Shen et al., 2016; Smith et al., 2014; Straussman et al., 2012) become hyperactivated in BRAFi-resistant melanoma. In addition to these described mechanisms, up to 40% of BRAFi-resistant tumors harbor unknown mechanisms of resistance (Johnson et al., 2015; Rizos et al., 2014) , and not all can be explained by genetic/genomic changes (Hugo et al., 2015) .
Common BRAFi resistance mechanisms, which reactivate MAPK or activate PI3K signaling, are typically thought to be acquired molecular alterations as opposed to selection of pre-existing tumor clones (Lackner et al., 2012) . Development of such mechanisms likely requires activation of cellular survival pathways to evade BRAFiinduced cell death until permanent resistance mechanisms are acquired.
The involvement of non-genomic alterations in the acquisition of BRAFi resistance has not been fully explored. MicroRNA (miRNA), which are modulators of gene expression and molecular pathways, play central roles in a variety of normal and pathological cellular processes (Lujambio and Lowe, 2012) . A few recent studies show involvement of miRNA in BRAFi resistance of melanoma. Vergani et al. (2016) demonstrate that a set of three miRNA (miR-34a, miR-100, and miR-125b) confers BRAFi resistance downstream of the chemokine CCL2, whereas Liu et al. (2015) identify miR-200c as a sensitizer of melanoma cells to BRAFi treatment. miR514a may contribute to BRAFi resistance, as its expression promotes survival of melanoma cells treated with BRAFi (Stark et al., 2015) ; however, evidence of miR514a modulation in clinical samples or models of BRAFi resistance has not been reported. Finally, Sun et al. (2016) found miR-7 downregulation in a model of BRAFi resistance and reported that its re-expression sensitized resistant cells to BRAFi treatment.
We hypothesized that specific miRNA can directly confer BRAFi resistance or contribute to the establishment of other resistance mechanism(s) that lead to MAPK and/or PI3K/Akt activation. To identify miRNA candidates that may contribute to BRAFi resistance in melanoma, we performed miRNA expression profiling of BRAFi-resistant cell clones and their respective parental cells. miR-125a was consistently overexpressed upon acquisition of resistance to BRAF inhibition. Upregulation of miR-125a was also observed in clinical BRAFi-treated tumors relative to paired, pretreatment tumor samples, further supporting its potential contribution to BRAFi therapeutic resistance. Mechanistically, we show that miR-125a facilitates BRAFi resistance by suppressing the intrinsic apoptotic pathway. Our findings support the possibility to use anti-miRNA-based approaches to prevent or overcome BRAFi resistance.
Results
MiR-125a is overexpressed in BRAFi-resistant melanoma To identify miRNA that may contribute to BRAFi resistance, we conducted miRNA expression profiling of BRAF V600E mutant SK-MEL-239 cells (BRAFi-sensitive cells) treated with DMSO or vemurafenib (Vem) for 24 h, and a panel of BRAFi-resistant cell clones generated through prolonged exposure to 2 lM vemurafenib (Poulikakos et al., 2011) . As previously reported, resistant clones universally reactivated the MAPK pathway (Figure 1A) and exhibited higher IC50 values compared with their parental counterpart ( Figure 1B ). We conducted expression profiling of 800 miRNA by NanoString of five BRAFi-resistant clones, DMSO-treated SK-MEL-239 cells, and SK-MEL-239 cells treated with vemurafenib for 24 h (Table S1 ). We observed miR-125a-5p consistently upregulated in all BRAFi-resistant clones analyzed (n = 5, Figure 1C ), a finding confirmed by RT-qPCR ( Figure S1A ). MiR-125a-5p induction was observed in multiple additional resistant SK-MEL-239 clones ( Figure 1D ) and other resistant cell lines ( Figure S1B ), as well as in BRAFi plus MEK inhibitor (MEKi) double-resistant cell clones (Figure S1C) . Importantly, we evaluated miR-125a expression in 22 paired human melanoma clinical samples acquired pretreatment and after BRAFi treatment. We observed miR125a-5p levels to be upregulated in eight of 22 (36%) tumor samples while on therapy with BRAFi ( Figure 1E ), supporting the potential relevance of miR-125a induction to development of therapeutic resistance to BRAFi in melanoma patients.
MiR-125a suppresses apoptosis in the presence of BRAFi and promotes BRAFi resistance We sought to determine whether miR-125a upregulation functionally contributes to the acquisition of resistance to BRAFi by melanoma cells. We stably overexpressed miR125a in SK-MEL-239 cells by lentiviral transduction ( Figure S2 ). MiR-125a-overexpressing cells displayed increased viability in the presence of vemurafenib at all tested doses (Figure 2A ). Moreover, miR-125a overexpression allowed melanoma cells to grow in the presence of BRAFi ( Figure 2B ). Interestingly, we observed that this resistance phenotype was not immediately accompanied by reactivation of the MAPK or AKT pathways (week 1, Figure 2C ), but resulted in enhanced reactivation of those pathways at later time points (weeks 2-4, Figure 2C ). As vemurafenib exerts its antitumor effect predominantly by triggering apoptosis , we examined the role of miR-125a on apoptosis induction of vemurafenibtreated melanoma cells. Ectopic expression of miR-125a in vemurafenib-treated cells significantly decreased the number of annexin + apoptotic cells ( Figure 2D ) and suppressed PARP cleavage ( Figure 2E ). Moreover, miR125a overexpression also conferred increased resistance to the combined treatment of BRAFi plus MEKi (Figure S3A, B) . Collectively, these data indicate that miR125a aids melanoma cell survival in the presence of BRAFi and promotes BRAFi resistance, likely through suppression of apoptosis.
MiR-125a inhibition suppresses the emergence of resistance to BRAFi and partially restores sensitivity to BRAFi in a subset of resistant cell lines Because miR-125a promotes melanoma cell survival during BRAFi treatment and its upregulation is maintained in BRAFi-resistant cells, we hypothesized that its inhibition may delay or prevent the emergence of resistance to BRAFi, suppress growth and survival of resistant cells, and/or resensitize resistant cells to BRAF inhibition. We stably downregulated miR-125a with a lentiviral vector expressing an antisense sequence ( Figure S4A ). MiR125a suppression in BRAFi-sensitive parental SK-MEL-239 cells did not have an effect on their viability in vitro ( Figure S4B , C), but yielded a significant reduction in the emergence of BRAFi-resistant colonies after prolonged exposure to vemurafenib ( Figure 3A) .
Next, we examined whether the miR-125a upregulation in established BRAFi-resistant cell clones is required to maintain resistance to BRAFi. Interestingly, in vitro, some resistant cell clones were partially resensitized to BRAF inhibition by miR-125a depletion ( Figure 3B ), by increasing vemurafenib-induced apoptosis ( Figure 3B , right panels); however, other resistant clones, which also overexpress miR-125a, were not resensitized to BRAF inhibition by miR-125a suppression ( Figure 3C ). In addition, miR-125a inhibition partially restored BRAFi sensitivity to non-clonal resistant A375 cells in vitro, further supporting the role of miR-125a in maintenance of BRAFi resistance ( Figure S4D) . In vivo, we tested the effect of miR-125a inhibition on the response to BRAFi treatment of a BRAFi-resistant clone. We observed that miR-125a depletion suppressed tumor growth, irrespective of BRAF inhibitor treatment. Collectively, these findings highlight The results in (A) are an average of three independent experiments; (B-E) are representative of three independent experiments AE standard deviation (SD). *P < 0.05, **P < 0.001, ***P < 0.0001, ****P < 0.00001. that miR-125a is important for establishment and, in some cases, for maintenance of BRAFi resistance in melanoma, suggesting these cells have become partially addicted to miR-125a for their proliferation.
MiR-125a suppresses the apoptotic program in BRAFi-treated melanoma cells. BAK1 and MLK3 are direct miR-125a targets To elucidate miR-125a effectors involved in BRAFi resistance, we performed RNA sequencing of SK-MEL-239 cells overexpressing miR-125a or a scrambled control, in the presence of vemurafenib or vehicle. Gene set enrichment analysis (GSEA) of deregulated genes (P < 0.05) in vemurafenib-treated miR-125a-overexpressing cells versus vemurafenib-treated scramble control cells revealed apoptosis as the main differentially regulated gene category (P < 0.00001; Figure 4A , upper graph). As miRNA are negative regulators of gene expression, we conducted GO analysis (http://da vid.abcc.ncifcrf.gov/) specifically for genes downregulated by miR-125a overexpression, which again identified 'apoptotic regulation' among the most significantly affected programs (P < 0.003) ( Figure 4A , lower graph). To identify direct targets, which might mediate miR-125a prosurvival effects in the presence of BRAFi, we overlapped the list of 1999 downregulated genes (P < 0.05, FC < 0.8) with a combined list of 2018 putative targets from three publicly available databases [TargetScan (Friedman et al., 2009) , Starbase (Li et al., 2014) , and miRWalk (Dweep et al., 2011) ]. Within the overlapping list of 503 putative targets downregulated by miR-125a overexpression in the presence of vemurafenib were several components of the intrinsic pro-apoptotic pathway (TXNIP, MLK2, MLK3, BIK1, BAK1, TP53; Figure 4B). Validation through Western blot analysis revealed regulation of MLK3 and BAK1 by miR-125a ( Figure 4C ), which was particularly evident upon BRAFi treatment. 3 0 UTR luciferase reporter assays confirmed that miR-125a directly targets both MLK3 and BAK1 ( Figure 4D ). Accordingly, resistant clones showed increased MLK3 and BAK1 protein levels after miR-125a inhibition ( Figure 4E ). Interestingly, miR-125a-induced repression of MLK3 did not affect the apoptotic JNK/ p38 pathway, which MLKs are known to regulate ( Figure S5A ).
Individual and combined silencing of BAK1 and MLK3 in SK-MEL-239 cells was unable to mimic the ability of miR125a to promote BRAFi resistance ( Figure S5B, C) , suggesting that miR-125a effects require the combined suppression of multiple apoptosis suppressors. However, in resistant cells sensitized to BRAFi through miR-125a inhibition, depletion of either BAK1 or MLK3 restored BRAFi resistance ( Figures 4F, S5D ). To examine whether downregulation of BAK1 and/or MLK3 correlated with resistance to BRAFi therapy in clinical samples, we analyzed their expression in a previously published profile (Rizos et al., 2014) of paired biopsies isolated pretreatment and at disease progression (BRAFi resistance) from 21 metastatic melanoma patients. There was evidence of downregulation (relative to the patientmatched pretreatment samples) of BAK1 or MLK3 in six (~29%) and 10 (~43%) of 21 patients, respectively ( Figure S5E ). These findings support that BAK1 and MLK3 downstream of miR-125a might be involved in clinical resistance to BRAFi therapy. Overall, these results suggest that regulation of pro-apoptotic targets might critically mediate miR-125a effects on melanoma cell resistance to BRAFi.
MiR-125a expression is regulated by TGFb signaling MiR-125a expression was induced after short-term vemurafenib exposure of SK-MEL-239 cells ( Figure S6A ) and rapidly returned to basal levels after drug removal ( Figure S6B ), suggesting that it is likely regulated by transient, reversible mechanisms. To examine whether this regulation occurs transcriptionally, we tested the effect of vemurafenib on the expression of the miR-125a primary transcript, which includes miR-125a, miR-99, and let-7b, and found it upregulated in resistant clones ( Figure S6C) . Surprisingly, of the miRNA expressed in this cluster, only mature miR-125a was found significantly upregulated ( Figure S6D ), suggesting that differential processing may add further specificity to the induction of miR-125a expression by BRAF inhibition.
To identify potential upstream regulators of miR-125a expression, we correlated miR-125a with coding mRNA abundance from a previously published gene expression profiling of a panel of melanoma cell lines (Rose et al., 2011) . Strikingly, the most highly correlated mRNA was TGFb1 (r 2 = 0.8, P < 0.00001; Figure 4G ), which has previously been implicated in acquisition of BRAFi resistance (Sun et al., 2014) . Moreover, in silico analysis of the miR-125a promoter region revealed three putative binding sites of the TGFb-induced gene EGR-1 (Chen et al., 2006) and one putative Smad binding site. Treatment of BRAFisensitive melanoma cells with recombinant TGFb1 protein induced miR-125a expression ( Figure 4H ). Importantly, TGFb signaling is induced upon vemurafenib treatment ( Figure 4I , left panel, Figure S7 ), and treatment with the TGFb receptor I inhibitor galunisertib suppressed miR125a induced by BRAF inhibition ( Figure 4I, right panel) . Overall, our data indicate that TGFb signaling contributes to miR-125a induction in response to BRAF inhibition.
Discussion
A major hurdle for targeted therapy in melanoma remains the widespread development of BRAFi resistance. Whereas most of the described resistance mechanisms are based on genomic alterations, the contributions of non-genomic alterations to resistance are only beginning to be explored (Hugo et al., 2015) . Delineating the molecular mechanisms involved in the acquisition and maintenance of BRAFi resistance may provide valuable insights into novel therapeutic strategies to more effectively treat patients with BRAF V600E -mutant melanoma. Here, in a model that recapitulates clinical BRAFi resistance (Poulikakos et al., 2011) and additional cell line models, we consistently observed upregulation of miR125a in BRAFi-resistant clones. Moreover, miR-125a was upregulated in human clinical melanoma samples from patients treated with BRAFi compared with their pretreatment biopsies. In addition to these observations, we experimentally demonstrated that miR-125a expression favors acquisition of BRAFi resistance by suppressing the induction of apoptosis via direct targeting of the intrinsic apoptotic pathway. Finally, we demonstrate that TGFb signaling is required for miR-125a induction during BRAFi treatment. Collectively, our data document a critical role of miR-125a supporting the acquisition of BRAFi resistance in melanoma. MiR-125a is a member of the miR-10 family, which also includes two homologs, hsa-miR-125b-1, hsa-miR-125b-2, with which miR-125a shares an identical seed region. MiR-125 homologs play crucial roles in many different cellular and molecular processes, such as differentiation, proliferation, apoptosis, and regulation of matrix metalloproteases (Balakrishnan et al., 2012; Bi et al., 2012; Bousquet et al., 2008; Ge et al., 2011; Sun et al., 2013; Xu et al., 2012) .
For the different miR-125 homologs, contrasting properties have been reported in different cancer types; they may contribute to the initiation and progression of cancers by acting as either tumor suppressors or oncogenes (Cowden Dahl et al., 2009; Jiang et al., 2010 Jiang et al., , 2011 . The opposing properties of the miR-125 homologs in different solid tumors demonstrate that they can have context-dependent functions in cancer pathogenesis, progression, and treatment resistance. The underlying direct target mediators and molecular mechanisms in different cell contexts require further investigation.
Although miR-125a has not yet been described as a mediator of acquired BRAFi resistance of melanoma cells, previous studies have documented the ability of miR125b to increase resistance of cancer cell models to anticancer agents (Sun et al., 2013; Zhou et al., 2010) . For instance, Sun et al. (2013) demonstrated a role for miR-125b in Taxol resistance in breast cancer. Moreover, recently, Vergani et al. (2016) reported that miR-125b (and other miRNAs) was upregulated in response to CCL2 induction during development of BRAFi resistance in melanoma. Similar to our findings for miR-125a, miR-125b blocked apoptotic induction, although the molecular mechanisms downstream of this phenotype are not yet elucidated. They did not observe miR-125a upregulation in their model of BRAFi resistance used for miRNA profiling, nor did we observe miR-125b induction in our models. It is tempting to speculate that context-dependent increase in one of the miR-125 homologs is required in the early stages of BRAFi treatment.
To our knowledge, our study provides the first evidence of miR-125a promoting therapeutic resistance in melanoma. Importantly, our findings identify a targetable step that may improve the efficacy of BRAF inhibition and/or BRAFi/MEKi combination therapy by blocking a cell survival pathway activated early in the treatment of metastatic BRAF mutant melanoma patients.
The prevalent BRAF V600E mutation provides melanoma cells with enhanced proliferation and survival signals. The therapeutic effects of BRAF inhibition stem from the activation of intrinsic apoptosis mechanisms. Our data suggest a mechanism of BRAFi-mediated cell death evasion, carried out by miR-125a and its direct targeting of the pro-apoptotic factors MLK3 and BAK1. MLKs commonly modulate apoptosis through the JNK/p38 pathway. In this study, we demonstrate that downregulation of the specific member MLK3 by miR-125a plays a role in resistance through increasing cell viability in a JNK/p38-independent manner. A possibility is that the low expression of MLK3 provides a survival advantage through the inactivation of the intrinsic apoptotic pathway via AMPK regulation (Luo et al., 2015) or other related factors. BAK1 functions as a pro-apoptotic regulator by localizing to mitochondria and accelerating the release of cytochrome c (Westphal et al., 2014) . Downregulation of BAK1 by miR125a therefore leads to a decrease in mitochondrial apoptotic signaling, effectively resulting in increased cell survival. Thus, the direct suppression of apoptosis by miR-125a provides a mechanism by which melanoma cells may evade BRAF inhibition. This general survival benefit enacted by miR-125a may permit tumor cells to acquire secondary, 'permanent' resistance mechanisms resulting in eventual reactivation of the MAPK and AKT pathways. Therefore, miR-125a upregulation likely coexists with other mechanisms of resistance, playing a supporting role for cell survival. This is supported by our observation that miR-125a inhibition suppressed tumor growth of BRAFi-resistant cells independent of BRAFi treatment. Whether miR-125a upregulation favors a particular subsequent resistance mechanism remains an area of active investigation.
As miRNA can have pleiotropic effects, suppression of apoptosis might not be the only mechanism by which miR125a contributes to resistance to BRAFi. Cells overexpressing the miRNA and treated with BRAFi exhibited phenotypic changes, such as lipid-like accumulations (data not shown), suggesting that alterations in cell metabolism might also be involved. In support of this notion, IPA analysis of genes modulated by miR-125a overexpression in the presence of BRAFi revealed 'cholesterol metabolism' among the top dysregulated categories. As cholesterol availability is altered in cancer cells and influences oncogenic networks (Ura et al., 1994) , investigating metabolic reprogramming of melanoma cells in relation to BRAFi resistance may provide further valuable insight. Accordingly, recent work has identified a metabolic shift toward oxidative phosphorylation as another response of melanoma cells to BRAFi (Haq et al., 2013a) .
Due to miR-125a targeting of pro-apoptotic factors, uncovering upstream miR-125a regulators in human tissues will likely provide relevant therapeutic avenues and is an area that warrants further investigation. In our system, the quick and reversible change in miR-125a expression levels upon BRAFi modulation suggests that it results from transcriptional and/or post-transcriptional mechanisms (rather than genetic amplification or mutation). We observed that TGFb signaling, induced by vemurafenib treatment, contributes to the regulation of miR-125a expression and therefore to resistance. Previous reports have linked activated TGFb signaling to the acquisition of BRAFi resistance (Sun et al., 2014) and miR-125a induction may critically contribute to those effects. While the upregulation of miR-125a provides a mechanism for drug resistance, the ability to target this miRNA opens the possibility to interfere with development of resistance. Indeed, depletion of this miRNA during BRAFi treatment in vitro led to a decreased emergence of resistant clones and partially resensitized a subset of BRAFi-resistant cells. These findings suggest potential benefit of establishing clinical approaches for miRNA suppression in combination with BRAFi or BRAFi/MEKi therapy in the treatment of BRAF V600E melanoma. Thus, the identification of miR-125a's involvement in BRAFi resistance elucidates clinically relevant mechanisms of melanoma cell survival and has important therapeutic implications.
Methods
Cells and cell culture SK-MEL-239 parental and some vemurafenib-resistant cell lines (single clones) were a kind gift from Dr. Poulikos Poulikakos and Dr. Emily Bernstein. Vemurafenib-resistant A375R and 451LuR cells (pooled clones) cells were derived from their respective parental cell lines by treatment with 1 lM vemurafenib for several weeks. A375 and 451Lu cells were cultured in Dulbecco's modified Eagle's medium, resistant single clones were derived from the SK-MEL-239 cell line through prolonged treatment with 2 lM vemurafenib (single resistance) or 1 lM vemurafenib + 2 lM PD0325901 (double resistance) in RPMI-1640 medium, supplemented with 10% fetal bovine serum and penicillin/streptomycin. The resistant cell lines were cultured in the presence of 1 lM vemurafenib. For TGFb experiments, cells were treated with human TGFb1 protein (R&D Systems, Minneapolis, MN, USA) or TGFb receptor I inhibitor (galunisertib, Selleckchem, Houston, TX, USA).
Cell line authentication by short tandem repeat (STR) analysis was performed for SK-MEL-239 at ATCC and confirmed that these cells did not match with any of the cell lines deposited in the cell bank (this cell line is not present in any of the main cell line repositories, and thus, there is no 'baseline' STR profile from which to compare). STR profiling is ongoing for A375 and 451Lu. Cell lines were previously analyzed by morphologic assessment and gene expression profiling for lineage-specific gene expression (TYR, TRYP1, DCT, TRYP1B, MITF, EDNRB, KIT) by microarray.
MiRNA expression profiling
Total RNA was extracted from SK-MEL-239 cells and derived resistant clones using QIAzol reagent (Qiagen, Germantown, MD, USA); 100 ng RNA per sample was used for miRNA profiling using the NanoString nCounter (Nanostring Technologies, Seattle, WA, USA) expression assay of 800 human miRNAs according to manufacturer's protocol (NanoString nCounter â miRNA Expression Assay User Manual). Raw expression values were normalized to those of the 100 highest expressed miRNAs and expression profiles were compared to the sensitive parental cells applying a differential expression cutoff of twofold. Student's t test analysis was conducted, and miRNAs with P-values <0.05 were selected for further analyses.
Pre-miRNA or anti-miRNA stable transduction 
Real-time quantitative PCR
Total RNA was isolated from cultured cells using the miRNeasy Mini Kit (Qiagen). MiRNA and pre-miRNA expression analysis was performed using miRNA-specific TaqMan MicroRNA Assay Kits (Applied Biosystems, part of Thermo Fisher Scientific, Foster City, CA, USA); 12.5 ng of total RNA were reverse-transcribed using the corresponding RT primer and the TaqMan microRNA Reverse Transcription Kit (Applied Biosystems). PCR was performed on 1.33 ll of RT products by adding TaqMan PCR primers and TaqMan Universal Master Mix (Applied Biosystems). RNU44 small RNA was used for normalization of input RNA/cDNA levels. MLK3 and BAK1 mRNA expression analysis was performed by synthesizing cDNA from 1 lg of total RNA using Reverse Transcriptase cDNA Synthesis kit (Applied Biosystems). For quantitative PCR, cDNA was mixed with SYBR Green PCR Master Mix (Applied Biosystems) and various sets of gene-specific primers and then subjected to RT-PCR quantification by using the iQ5 real-time PCR system (Bio-Rad, Hercules, CA, USA). The sequences of the primers used were as follows: 
FACS analysis
Cells were pretreated with annexin V-Pacific Blue (BioLegend, San Diego, CA, USA) and propidium iodide (PromoKine, part of PromoCell GmbH, Heidelberg, Germany) and analyzed with a BD LSR II (BD Biosciences, Franklin Lakes, NJ, USA) and FACS EXPRESS software (De Novo Software, Glendale, CA, USA). After an initial gating on forward-versus-side scatter plots, apoptotic cells were identified through gating for the annexin V + /PI + and annexin V + cells.
Western blotting
Cell lysates were harvested using a commercial cell lysis buffer (Cell Signaling, Danvers, MA, USA) supplemented with protease (complete protease inhibitor cocktail) and phosphatase (PhosSTOP) inhibitors (Roche, via Sigma Aldrich, Allentown, PA, USA). Cell lysates (25-30 lg) were resolved in Tris/glycine or Bis-Tris SDS/ PAGE gels (Invitrogen) and transferred to nitrocellulose or PVDF membranes (Invitrogen). Membranes were blocked with 5% non-fat milk or 5% BSA in TBS-T for 60 min and probed with primary antibodies overnight at 4°C for BIK (Abcam, Cambridge, MA, USA), MLK2 (Abcam), MLK3 (Abcam), tubulin (Sigma Aldrich), TXNIP (VDUP-1) (Invitrogen), BAK1, TP53, JNK, pJNK (Thr183/Tyr185), p38, p-p38 (Thr180/Tyr182), ERK, pERK (Thr202/Tyr204), AKT, pAKT (Ser473) (Cell Signaling). Membranes were exposed to HRP-or fluorescence-conjugated secondary antibodies (1:10 000) in TBS-T with 1% blocking agent for 60 min. Following extensive washing with TBS-T, Western membranes were digitally imaged (fluorescent, Li-Cor) or developed with the ECL Western blotting detection kit (HRP, EMD Millipore, Billerica, MA, USA) and exposed on film (Denville Scientific, Holliston, MA, USA).
Luciferase assay
A plasmid containing the luciferase cDNA conjugated to the 3 0 UTR of MLK3 was purchased from SwitchGear Genomics (Menlo Park, CA, USA). A plasmid containing the luciferase cDNA conjugated to the 3 0 UTR of BAK1 was purchased from GeneCopoeia (Rockville, MD, USA). HEK293T cells were seeded into a 96-well plate and cotransfected with 3 0 UTR reporter vectors and indicated amounts of miRIDIAN miR-125a or miR-182 mimics or mimic negative control (Dharmacon). Luciferase activity was measured using the Dual-Glo Luciferase Assay System (Promega, Madison, WI, USA). Renilla luciferase activity was normalized to corresponding firefly luciferase activity and plotted as a percentage of the control.
Cell viability assay
Cells were seeded into a 96-well plate and treated with indicated concentrations of vemurafenib (Plexxikon, Berkeley, CA, USA) (0.001-100 lM); 96 h after treatment, cell viability was measured using the CellTiter Glo Luminescent Cell Viability Assay (Promega) according to manufacturer's instructions.
Short-term proliferation assay
Cells were seeded into a 96-well plate and treated with 2 lM vemurafenib (Plexxikon) for indicated times. Cells were then fixed using 1% glutaraldehyde and stained with crystal violet. Dye was then solubilized using 15% acetic acid and read at OD590.
Long-term proliferation assay
Cells were seeded in triplicate into six-well plates and treated with DMSO or 2 lM vemurafenib (Plexxikon) for the indicated time points. At each time point, cells were counted and cell numbers were referred to initial seeding at day 0.
In vivo xenograft experiment with resistant cells 1 9 106 cells (resistant clone 4 transduced with Zscr or Z125a) were injected in one flank/mouse of 20 mice per group. Tumors began to form at 1 week after injection. Drug treatment was initiated at 100 mm 3 tumor volume; 10 mice per group were injected with 25 mg/kg vemurafenib or DMSO through intraperitoneal injection twice per day for 24 days.
Clinical specimens
Patients with BRAF V600 -mutant metastatic melanoma were treated with a BRAFi. After obtaining appropriate Institutional Review Boardapproved protocol, 7-lm formalin-fixed and paraffin-embedded (FFPE) sections were received from tumors biopsied before treatment or at the time of progression.
FFPE RNA Isolation
Human metastatic melanoma areas were identified through H&E staining by an experienced pathologist (Dr. Farbod Darvishian). Tumor areas were microdissected using a precision scalpel.
Depending on tumor size, 3-5 sections per sample, each 7 lM thick, were used per RNA extraction. RNA was extracted using the QIAGEN miRNeasy FFPE Tissue Kit (Qiagen) according to manufacturer's protocol.
RNA sequencing
Total RNA was extracted using the miRNeasy Mini Kit (Qiagen). Total RNA quality and quantity were determined using Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and Nanodrop ND-1000 (Nanodrop, part of Thermo Scientific, Wilmington, DE, USA). Expression profiling of the duplicate experimental sample groups (SK-MEL-239 cells with lentiviral scramble or miR125a constructs after 7 days of DMSO or 2 lM vemurafenib treatment) was performed using Illumina HiSeq 2500 System (Illumina, San Diego, CA, USA). Samples were subject to PolyA selection using oligo-dT beads and the resulting RNA samples were then used as input for library construction according to the manufacturer's instructions (Illumina TruSeq RNA Sample Prep Kit v2). RNA libraries were then sequenced on the Illumina HiSeq2500 using paired-end sequencing with v4 technology.
RNA sequencing data analysis
Sequencing results were demultiplexed and converted to FASTQ format using ILLUMINA BCL2FASTQ software (Illumina). Paired-end reads were aligned to the human genome (build hg19/GRCh37) using the splice-aware STAR aligner (Dobin et al., 2013) . PCR duplicates were removed using the Picard toolkit (http://broadinstitute.github.io/pica rd/). HTSeq package (Anders et al., 2015) was utilized to generate counts for each gene based on how many aligned reads overlap its exons. These counts were then used to test for differential expression using negative binomial generalized linear models implemented by the DESeq2 R package (Love et al., 2014) .
The functional annotations of the gene lists were performed using the NIH web-based tool DAVID (Database for Annotation, Visualization and Integrated Discovery) (Huang et al., 2009 ) and/or GSEA (http://www.broadinstitute.org/gsea/) (Subramanian et al., 2008) .
Statistical methodologies
Unless otherwise indicated, mean values AE SD are representative of one of three independent experiments. Statistical significance was determined by Student's t test (GRAPHPAD PRISM software; GraphPad Software, Inc., La Jolla, CA, USA). Of note, *P < 0.05; **P < 0.001; and ***P < 0.0001, ****P < 0.00001.
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